Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami +6 more
wiley +1 more source
Efficacy of polyglycolic acid sheet plus oral steroid on the esophageal stricture after endoscopic submucosal dissection: a propensity score matched retrospective study. [PDF]
Zhang M +5 more
europepmc +1 more source
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui +15 more
wiley +1 more source
Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild‐to‐moderate psoriasis
Balinatunfib is the first oral, small molecule selective inhibitor of TNFR1 signaling. The results of this study indicate that balinatunfib treatment was tolerable with no serious or severe adverse events in patients with mild‐to‐moderate psoriasis and showed clinical responses.
Nassr Nassr +10 more
wiley +1 more source
Biomechanical assessment of the maxillary position after Le Fort I osteotomy using rapidly biodegradable miniplates and screws: an experimental study. [PDF]
Sukegawa S +5 more
europepmc +1 more source
French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault +51 more
wiley +1 more source
Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study. [PDF]
Nikoloudaki M +15 more
europepmc +1 more source
Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth +8 more
wiley +1 more source
Clinical significance of intraoperative amylase levels on intra-abdominal exudates in the prediction of postoperative drain amylase levels after gastric cancer surgery. [PDF]
Tsuru Y, Noshiro H, Tanaka T, Yoda Y.
europepmc +1 more source
ABSTRACT Objective To evaluate the clinical application and outcomes of the inverted T‐shape connective tissue graft (IT‐CTG) technique for reconstructing deficient interdental papillae in cases of advanced gingival recession, focusing on both quantitative and qualitative results in a consecutive case series.
Abdusalam E. Alrmali +4 more
wiley +1 more source

